JMP Securities reiterated their market outperform rating on shares of Altimmune (NASDAQ:ALT – Get Rating) in a report released on Friday, Benzinga reports. They currently have a $15.00 target price on the stock. Several other research analysts have also weighed in on the stock. Evercore ISI upped their price objective on shares of Altimmune from […]
NASH Renaissance 2023 Pemvidutide-Potent GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH and Obesity Evercore ISI Research. | March 30, 2023
Altimmune, Inc. (NASDAQ:ALT – Get Rating) Director David Drutz purchased 9,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were bought at an average cost of $4.27 per share, for a total transaction of $38,430.00. Following the completion of the acquisition, the director now directly owns 29,484 […]
Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
On March 27, 2023, the Board of Directors of Altimmune, Inc. appointed. | March 27, 2023
Shares of Altimmune, Inc. (NASDAQ:ALT – Get Rating) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 […]